Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. Octreotide acetate inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone. Octreotide also reduces gastrointestinal motility and inhibits contraction of the gall bladder.
First approved for use in the United States in 1988, this longer-acting synthetic peptide is primarily used for the reduction of growth hormone and insulin-like growth factor 1 primarily used in adults with acromegaly and pituitary giantism. was developed by the pharmaceutical company Sandoz.
The chemical structure of octreotide acetate is designed to mimic the structure and actions of somatostatin, a naturally occurring peptide hormone. By modifying somatostatin in this way, octreotide acetate gains a longer duration of action and increased stability in the body, making it suitable for therapeutic use in various medical conditions.